跳至主要内容
临床试验/NCT01338376
NCT01338376Unknown4 期

Organization Program of DiabEtes INsulIN ManaGement: An Open, Multi-center, Prospective, Randomized, 16-week, Controlled Clinical Study

Chinese Diabetes Society1 个研究点 分布在 1 个国家目标入组 1,500 人开始时间: 2011年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
发起方
入组人数
1,500
试验地点
1
主要终点
HbA1c

研究概览

简要总结

Diabetes is a common, costly condition associated with significant morbidity and mortality. Diabetes self-management education, the process of teaching individuals to manage their diabetes, has been considered an important part. The intensive education has the capacity to deliver effective interventions to a large number of people. The investigators may be able to redirect our efforts to diabetes care and education strategies that will have a positive impact on the optimization of glycemic control and the prevention of long-term complications of diabetes, reducing the subsequent human and health care costs.

详细描述

This is a prospective, randomized, open-label, controlled clinical study. 1500 subjects with Type 2 DM will be enrolled and be randomized into Structured Education Group and Conventional Education Group in 1:1 ratio. Subjects in both of the groups will be treated with Scilin®M30 twice daily (30 minutes before breakfast and dinner). All the previous oral antidiabetic drugs (OAD(s)) will be discontinued except metformin and alpha-Glucosidase Inhibitors. The physician will determine the starting dose (0.3 IU/kg~0.4IU/kg), as well as later changes to dose according to insulin titration algorithm. The treatment duration will last 16 weeks.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Written Informed Consent obtained before any trial-related activities Type 2 DM subjects;
  • Age > 18 years old,male or female;
  • Continuous treated with two or more oral antidiabetic drugs (OADs) for the last 3 months,and the current HbA1c>7.5%;
  • Cooperative with structured management;

排除标准

  • Subjects with type 1 diabetes;
  • Gestational diabetes mellitus and other specific types DM;
  • Those who are unwilling to sign in ICF;
  • Subjects with repeated hypoglycemia;
  • Subjects with BMI>30kg/m2;
  • Impaired liver function,defined as alanine aminotransferase (ALAT)>= 2.5 or alkaline phosphatase (ALP)>= 2 times upper referenced limit times upper normal limit;
  • Females of childbearing age who are pregnant, breast-feeding or have the intention of becoming pregnant or not using adequate contraceptive methods throughout the trial (adequate contraceptive measures as required by local law or practice);
  • Mental incapacity, unwillingness, or language barrier precluding adequate understanding or cooperation;
  • Any other clinically significant condition or major systemic diseases, including serious coronary heart disease, cardiovascular disease, myocardial infarction within the past 12 months; severe neurology or psychology or psychiatric diseases; serious infection; actively disseminated intravascular coagulation;
  • Malignant neoplastic diseases (except carcinoma in situ);
  • Current addiction to alcohol or other addictive substances;

研究组 & 干预措施

Structured Education Group

Experimental

Subjects received structured diabetes education

干预措施: Scilin®M30 (Drug)

Structured Education Group

Experimental

Subjects received structured diabetes education

干预措施: Structured Education (Behavioral)

Conventional Care Group:

Active Comparator

Subjects received conventional diabetes education

干预措施: Conventional Diabetes Education (Behavioral)

Conventional Care Group:

Active Comparator

Subjects received conventional diabetes education

干预措施: Scilin®M30 (Drug)

结局指标

主要结局

HbA1c

时间窗: Screen,16weeks

Investigate glycemic control as measured by HbA1c change

次要结局

  • Diabetes self-management skills Diabetes self-management skills Assess diabetes self-care ability by Diabetes Self-Management (SDSCA)(Screen,16weeks)
  • Assess diabetes self-management ability by Diabetes Management Self-Efficacy (C-DMSES)(Screen,16weeks)
  • The satisfaction degree of structured management(Screen,2weeks,4weeks,8weeks,12weeks,16weeks)
  • total daily insulin dose(1week,2weeks,3weeks,4weeks,6weeks,8weeks,12weeks,16weeks)
  • 7-points of glucose(Screen,16weeks)
  • body weight(baseline,2weeks,4weeks,8weeks,12weeks,16weeks)
  • Medication compliance(Screen,16weeks)
  • The incidence of Hypoglycemia(1week,2weeks,3weeks,4weeks,6weeks,8weeks,12weeks,16weeks)

研究者

发起方
Chinese Diabetes Society
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验